DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

A novel study published in the journal PLOS ONE highlighted the effects of hydroxychloroquine on cardiovascular risk factors ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus, or SLE. The results were shared during an oral, late-breaker ...

showing significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus. Dapirolizumab pegol met its primary endpoint, demonstrating ...

Fate said it is also enrolling a second treatment arm under the Phase 1 Autoimmunity study to evaluate a single dose of FT819 ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...